Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Go back to Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 33.85 +1.48 (4.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.37 | 52 Week High | $5.17 | |||
| Open | $32.18 | 52 Week Low | $0.94 | |||
| Day High | $34.20 | P/E | N/A | |||
| Day Low | $31.76 | EPS | $0.00 | |||
| Volume | 549,286 | |||||
